Genetics & Genomics

Nurse navigators have a valuable role to play in advancing policies that bring biomarker testing to more patients.

When it comes to cancer genetic testing and counseling, role delineation between oncology nurse navigators, patient navigators, and genetic counselors is vital to avoiding overlap of responsibilities and delivering quality patient care.

Over the past 5 years, there have been 20 FDA approvals of novel genetic medicine technologies – and this is just the beginning. Here’s a glimpse of what’s coming ahead.

In this roundtable discussion presented by AONN+ and supported by Exact Sciences, a panel of experts discuss the critical role of nurse navigators in educating cancer patients about genomic testing and how to interpret the results.

Real-world data indicate that genetic testing and personalized medicine is rarely applied in the community setting for patients with hepatobiliary and pancreatic cancers.

Proceedings from key sessions from an AONN+ conference are presented in this CEU activity.

Navigators can meet the ever-growing needs of patients undergoing genetic testing. Here’s how.

KRAS-mutant tumors are notoriously difficult to treat. Early data presented at the 2020 virtual meeting of the American Association for Cancer Research suggest 2 new routes to treating KRAS-mutated cancers: (1) the combination of a RAF/MEK inhibitor and a FAK inhibitor, and (2) onvansertib, a competitive inhibitor of the PLK1 enzyme, together with chemotherapy.

Understanding the functions of different tissues in the body is key to understanding genetics and genomics.

Incorporating genetics and genomics in oncology nursing care is key to advancing treatment modalities and care for current and future patients.